PRELAJ, ARSELA

PRELAJ, ARSELA  

DIPARTIMENTO DI ELETTRONICA, INFORMAZIONE E BIOINGEGNERIA  

Mostra records
Risultati 1 - 20 di 41 (tempo di esecuzione: 0.047 secondi).
Titolo Data di pubblicazione Autori File
178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients 1-gen-2023 Provenzano, L.Favali, M.Mazzeo, L.Trovò, F.Pedrocchi, A.Miskovic, V.Prelaj, A. +
Abstract PO-065: Artificial intelligence to improve selection for NSCLC patients treated with immunotherapy 1-gen-2021 Prelaj, ArselaRestelli, MarcelloPedrocchi, AlessandraTrovo, Francesco +
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? 1-gen-2020 Prelaj A. +
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 1-gen-2023 Prelaj, ArselaProvenzano, LeonardoMazzeo, LauraManglaviti, SaraAmbrosini, PaoloPedrocchi, Alessandra Laura GiuliaMiskovic, Vanja +
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 1-gen-2024 Prelaj, A.Miskovic, V.Trovo, F.Mazzeo, L.Provenzano, L.Favali, M.Ambrosini, E.Pedrocchi, A. L. G. +
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 1-gen-2021 Prelaj A. +
Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma 1-gen-2021 Prelaj, Arsela +
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation 1-gen-2022 Prelaj, ArselaManglaviti, Sara +
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis 1-gen-2021 Prelaj A. +
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 1-gen-2019 Prelaj A. +
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 1-gen-2019 Prelaj A. +
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer 1-gen-2022 Prelaj, Arsela +
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation 1-gen-2020 Prelaj A. +
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 1-gen-2019 Prelaj A. +
Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort 1-gen-2019 Prelaj A. +
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy 1-gen-2020 Prelaj A. +
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 1-gen-2021 Prelaj, Arsela +
Exploring the role of respiratory microbiome in lung cancer: A systematic review 1-gen-2021 Prelaj, Arsela +
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis 1-gen-2020 Prelaj, A +
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 1-gen-2022 Prelaj, Arsela +